Drug intelligence / Profile preview

MCC-2

Development stage: Preclinical
Lead developer: University of Southern California
Modality: Small Molecules

Overview

MCC-2 is a synthetic analog of (-)-epigallocatechin gallate (EGCG) developed by researchers at the University of Southern California. Designed to overcome the poor bioavailability, stability, and membrane permeability of native EGCG, MCC-2 serves as an immunomodulatory and antibacterial agent. It potentiates the host immune system to clear intracellular reservoirs of Staphylococcus aureus (including methicillin-resistant S. aureus, or MRSA) in macrophages and whole blood by activating the 67 kDa laminin receptor (67LR, also known as ribosomal protein SA) pathway. Additionally, MCC-2 exhibits direct antibacterial activity and works synergistically with standard antibiotics like beta-lactams to restore susceptibility in resistant strains.

Other names: EGCG analog MCC-2epigallocatechin gallate analog MCC-2

Targets

RPSA (37/67 kDa laminin receptor)

Beyond the preview

Go deeper on MCC-2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MCC-2.